The fast-acting insulin, which diabetics inject shortly before each meal, is used by about 700,000 Americans.
Increasingly, top researchers are questioning whether drugs such as Lantus from Sanofi, Levemir and Novolog from Novo Nordisk A/S, and Humalog from Eli Lilly and Co. are really needed for many patients.
Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
The company, which employs more than 3,000 on the northeast side, has been struggling on the diabetes side of its business. To bounce back, it is investing heavily in diagnostics, and is working to commercialize several products it hopes will be game-changers.
The American Medical Association recently called on regulators to monitor competition among the three drugmakers who control the market—Indianapolis-based Eli Lilly and Co., Denmark-based Novo Nordisk and Paris-based Sanofi.
The newly built farm uses a high-fat, high-cholesterol diet to give animals heart disease and diabetes to help medical researchers find treatments.
A five-year, $7 million program is led and supported by a coalition of local health institutions, including Eli Lilly and Co., Fairbanks School of Public Health and Eskenazi Health. It is based on a model that Lilly has used in other countries.
Since starting a wellness program in 2010, IndyGo has seen employee participation climb from just a few, skeptical workers to 97 percent of the workforce.
Roche Holding AG—the Basel, Switzerland-based parent of Indianapolis-based Roche Diagnostics—has enlisted a little green gremlin to help rescue its diabetes business after a decade of declining sales.
A recently unsealed suit accuses the Indianapolis-based drugmaker of offering free nursing services to doctors to induce them to prescribe the company’s products.
Global pharmaceutical companies including Indianapolis-based Eli Lilly and Co. are heading into smaller cities and rural areas to learn about the health care needs of about 70 percent of India’s population.
Roche Group is rolling out a new blood-glucose meter and a savings program for test strips, which it says it will make diabetes care more affordable.
Shares in Eli Lilly and Co. stock fell more than 3 percent Tuesday after the Indianapolis-based drugmaker released a quarterly earnings report that showed sales of potential blockbuster drug Jardiance missed expectations by a wide margin.
Two Indianapolis-based subsidiaries of Swiss pharmaceutical giant Roche Group are accusing a group of pharmacies and supply houses of engaging in an elaborate scheme to defraud Roche of millions of dollars worth of sales on diabetes test strips.
The expansion at the Lilly Technology Center southwest of downtown is part of an $850 million investment the company is making this year in its U.S. research labs, manufacturing plants and other operations.
Eli Lilly and Co. will bypass insurance companies to offer a discount on its best-selling insulin products for patients who lack health coverage or have high deductibles that require them to pay the full cost of some medications.
In a few days, a new type of knockoff medicine will upend a $10 billion diabetes-drug market and exacerbate a brutal price war between some of its biggest players.